WallStSmart

Merck & Company Inc (MRK)vsYD Bio Ltd (YDES)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 5436679% more annual revenue ($67.38B vs $1.24M). YDES leads profitability with a 24.7% profit margin vs 3.6%. MRK earns a higher WallStSmart Score of 42/100 (D).

MRK

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

YDES

Avoid

32

out of 100

Grade: F

Growth: 6.3Profit: 3.5Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -2.29
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-74.0%)

Margin of Safety

-74.0%

Fair Value

$84.93

Current Price

$144.52

$59.59 premium

UndervaluedFair: $84.93Overvalued

Intrinsic value data unavailable for YDES.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$362.27B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

YDES3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
314.9%10/10

Revenue surging 314.9% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Profit MarginProfitability
24.7%9/10

Keeps 25 of every $100 in revenue as profit

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

YDES4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$422.86M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Price/BookValuation
81.3x2/10

Trading at 81.3x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : YDES

The strongest argument for YDES centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at -382.1%. Revenue growth of 314.9% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : YDES

The primary concerns for YDES are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

MRK profiles as a value stock while YDES is a growth play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.12 — expect wider price swings.

YDES is growing revenue faster at 314.9% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (42/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

YD Bio Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.

Want to dig deeper into these stocks?